May 20, 2021
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...
Read More
May 19, 2021
CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation
CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...
Read More
May 4, 2021
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...
Read More
March 1, 2021
CatalYm Announces Key Management and Board Changes
CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...
Read More
January 28, 2021
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...
Read More
November 10, 2020
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...
Read More
June 18, 2020
CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020
CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of...
Read More